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ABSTRACT 
Objective: The present study was designed to investigate the neuroprotective potential of nebivolol, a β1 adrenergic blocker on aluminium-induced 
neurobehavioral and biochemical alterations in rats.  
Methods: The neurotoxicity was induced by administration of aluminium (50 mg/kg/day, p.o.) for 5 weeks. Nebivolol was administered at a dose of 
10 mg/kg, p.o. for 5 weeks. Behavioral assessments were done by using open field test and modified elevated plus maze (mEPM) test. At the end of 
the study, oxidative stress parameters were determined and histopathological studies of cerebral cortex of rat brains were performed.  
Results: Aluminium chloride treated rats showed significant reduction in motor activity in open field test and memory impairment in mEPM test as 
compared to control group. Nebivolol significantly reversed these parameters and restored brain antioxidant defensive enzymes with reduction in 
lipid peroxidation. The neurotoxicity was confirmed by the histopathological analysis of cerebral cortex of rat brains. Aluminium treated animals 
showed presence of ghost cells, vacuolated cytoplasm and haemorrhage in rat cerebral cortex, indicating neurotoxicity. Nebivolol attenuated all 
these changes. Thus, the potential of nebivolol to prevent aluminium-induced neurotoxicity was also reflected at microscopic level, indicative of its 
neuroprotective effects.  
Conclusion: Nebivolol showed significant antioxidant and neuroprotective activities against aluminium-induced neuronal degeneration. The results 
of the present study strengthen oxidative stress hypothesis of aluminium-induced neurotoxicity and suggest beneficial role of nebivolol in the 
treatment of neurodegenerative disorders.  
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INTRODUCTION 
Aluminium (Al) is one of the leading causes of several neuro-
degenerative conditions such as Alzheimer’s disease [1]. High 
abundance of aluminium in degenerating neurons has proved the 
fact that aluminium is responsible for neuro-degeneration [2]. Many 
hypotheses have been put forth in order to propose possible 
mechanisms of aluminium-induced neuronal degeneration. These 
hypotheses suggest involvement of oxidative stress [3], disruption of 
calcium homeostasis and deterioration of intracellular signal 
transduction pathways [4]. Aluminium is known to interfere with 
cholinergic [5], serotonergic [6], glutamatergic, and gamma-
aminobutyric acid (GABA) neurotransmission [7].  
Exposure to aluminium is also known to interfere with the 
acetylcholine metabolism. Aluminium causes increase in 
acetylcholinesterase activity [8]. The glutamate level was found to 
be increased significantly in the brain regions of the aluminium-
treated rats [9]. Many researchers have proved that exposure to high 
concentrations of aluminium may lead to oxidative stress and rise in 
reactive oxygen species production in cells, causing lipid 
peroxidation, influencing the action of diverse antioxidant enzymes 
including catalase, superoxide dismutase, glutathione peroxidase 
and stimulating protein oxidation [10]. The nervous system is 
particularly susceptible to oxidative damage, as the brain has a high 
oxygen consumption rate. Aluminium deposits have been found to 
be present around the blood vessels in patients with dementia. 
Nebivolol is a third-generation β1 adrenergic blocker with peculiar 
pharmacological properties compared with other beta blockers. 
Nebivolol possesses free radical scavenging activity with promising 
antioxidant properties [11].  
One of the mechanisms of nebivolol's antioxidant activity is due to a 
reduction of reactive oxygen species (ROS) produced by a NADPH 
oxidase system [12]. It has been proved that, along with its peculiar 
anti-oxidant activity, nebivolol, but not other beta-blockers, 
improves endothelial function, reduces vascular superoxide 
production via prevention of eNOS uncoupling, reduces vascular 
macrophage infiltration, and inhibits NADPH oxidase-dependent 
superoxide production in neutrophils [13]. In spite of the reported 
antioxidant property of nebivolol in a variety of models, we found 
the focus of existing research is not on neuroprotective effect of 
nebivolol. Therefore, in this study, we have investigated the possible 
beneficial effects of nebivolol in aluminum-induced neurotoxicity 
and measures of oxidative stress in rats. 
MATERIALS AND METHODS 
Drugs and Chemicals  
Nebivolol hydrochloride (Hetero Labs, Hyderabad, India); 
aluminium chloride (Research-Lab Fine Chem Industries, Mumbai, 
India); nitrobluetetrazolium chloride (NBT) (Himedia Laboratories 
Pvt. Ltd. Mumbai, India); selegiline (Intas Pharmaceuticals Ltd., 
Ahmedabad, India); thiobarbituric acid (TBA) (Research-Lab Fine 
Chem Industries, Mumbai, India); 5, 5’- dithiobis-2-nitro benzoic 
acid (DTNB) (Alfa Aesar, A Johnson Mathey Company); bovine serum 
albumin (Spectrochem Pvt. Ltd., Mumbai, India). All the chemicals 
used were of analytical grade and purchased from standard 
manufacturers. 
Animals  
Male Wistar rats (230-250 g) were used for the study. Animals were 
housed in polypropylene cages and maintained under the standard 
laboratory environmental conditions; temperature 25 ± 2ºC, 12: 12 
h L: D cycle and 50 ± 5% RH with free access to food and water ad 
libitum. Animals were acclimatized to laboratory conditions before 
the test. 
The studies were carried out in accordance with the guidelines given 
by Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), New Delhi (India). The 
Institutional Animal Ethical Committee of M.V.P.S College of 
Pharmacy, Nashik (India) approved the protocol of the study 
(IAEC/2013/1b).  
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Experimental design 
Animals were randomly divided into four groups of six animals each: 
(a) Group I – Control (distilled water only); (b) Group II – Aluminium 
chloride (50 mg/kg/day, p.o.) for five weeks; (c) Group III – 
Aluminium chloride (50 mg/kg/day, p.o. for five weeks) + nebivolol 
(10 mg/kg/day, p.o.) for five weeks. Nebivolol has shown successful 
recovery from oxidative stress at this dose in previous studies [14]; 
(d) Group IV – Aluminium chloride (50 mg/kg/day, p.o. for five 
weeks) + selegiline (0.49 mg/kg/day, p.o.) for five weeks. 
Aluminium was administered in the form of AlCl3 which was 
dissolved in distilled water and was administered through oral 
gavage. Nebivolol was suspended in 0.2% polyethylene glycol (PEG-
400) for oral administration.  
Nebivolol and selegiline were given 60 minutes before 
administration of aluminium. The experimental protocol was 
developed according to the procedure described by Jyoti et al. with 
slight modifications [15]. 
Behavioral study 
Open field test 
Locomotor activity was evaluated in an open field paradigm. The 
open field was made up of plywood and consisted of floor (96 × 96 
cm) with high walls (61 × 61 cm). Entire apparatus was painted 
black except for 6 mm thick white lines that divided the floor into 
sixteen squares. Each animal was placed at one corner of the 
apparatus and was observed up to five minutes for ambulations 
(number of squares crossed), number of rearings and latency to 
reach at centre of the open field. The test was performed on 1st, 15th, 
25th and 35th days. Before each trial, field was cleaned thoroughly 
with 0.1% acetic acid solution [16]. 
Modified Elevated plus maze test (mEPM) 
EPM test is primarily used for measurement of anxiety in rodents 
and is modified to evaluate spatial learning and memory [17]. This 
test was carried according to the procedure described by Hlinak & 
Krejci (2000) with slight modifications. The plus-maze consisted of 
two opposite open arms 50 × 10 cm crossed with two closed arms of 
the same dimensions with walls 40 cm high. The arms were 
connected with a central square 10 × 10 cm to give the apparatus a 
plus-sign appearance.  
The maze was elevated 30 cm above the floor. At the start of 
experiment, each rat was gently placed at the end of an open arm of 
the apparatus facing away from the central platform and the time 
taken to move from the open arm to either of the enclosed arms 
(transfer latency) was recorded. An entry was defined when both of 
the forepaws were on the arm. After entering the enclosed arm, the 
rat was allowed to move freely in the maze regardless of open and 
enclosed arms for 10 s. To remove any confounding olfactory cues 
the maze was cleaned with alcohol and water solution after each 
trial. The experiments were conducted in a semi-sound proof room 
under a natural illumination. The transfer latency was measured on 
34th and 35th days [18]. 
Biochemical estimations 
Dissection and Homogenization 
On the 35th day immediately after behavioral assessments, the 
animals were killed by cervical decapitation. The brain was 
removed, rinsed with isotonic saline and weighted. A 10 % (w/v) 
tissue homogenate was prepared in 0.1 M phosphate buffer (pH 7.4). 
The post nuclear fraction for catalase assay was obtained by 
centrifugation (Remi - C - 30, Remi Industries Ltd. Mumbai, India) of 
the homogenate at 1000 g for 20 min at 4ºC; for other enzyme 
assays, centrifugation was at 12000 g for 60 min at 4ºC. A 
Biospectrophotometer (Elico BL-200) was used for subsequent 
assays [19]. 
Catalase activity (CAT) 
Catalase activity was assessed by the method of Luck (1971), where 
the breakdown of H2O2 was measured at 240 nm. Briefly, the assay 
mixture consisted of 3 ml of H2O2 phosphate buffer (0.0125 M H2O2) 
and 0.05 ml of supernatant of brain homogenate and the change in 
the absorbance was measured at 240 nm. The enzyme activity was 
calculated using the millimolar extension coefficient of H2O2 (0.07). 
The results were expressed as micro moles of H2O2 decomposed per 
minute per milligram of protein [20]. 
Estimation of reduced glutathione (GSH) 
Reduced glutathione (GSH) in the brain was assayed according to the 
method of Ellman (1959). A 0.75 ml sample of homogenate was 
precipitated with 0.75 ml of 4% sulphosalicylic acid. The samples 
were centrifuged at 1200×g for 15 min at 4 ºC. The assay mixture 
contained 0.5 ml supernatant and 4.5 ml of 0.01 M DTNB [5-5’-
dithiobis (2-nitrobenzoic acid)] in 0.1 M phosphate buffer, pH 8.0. 
The yellow colour developed was read immediately at 412 nm. The 
results were expressed as micro moles of GSH per milligram of 
proteins [21]. 
Superoxide dismutase activity (SOD) 
Superoxide dismutase activity was assayed according to the method 
of Kono (1978), wherein the reduction of nitrobluetetrazolium 
chloride (NBT) was inhibited by the superoxide dismutase and 
measured at 560 nm spectrophotometrically. Briefly the reaction 
was initiated by the addition of hydroxylamine hydrochloride to the 
reaction mixture containing NBT and post nuclear fraction of brain 
homogenate. Results were expressed as percentage inhibition of 
reduction of NBT [22]. 
Lipid peroxidation assay (LPO) 
The quantitative measurement of lipid peroxidation in brain was 
done by the method of Wills (1966). The amount of 
malondialdehyde (MDA) formed was measured by reaction with 
thiobarbituric acid at 532 nm. The results were expressed as 
nanomoles of MDA per milligram of protein, using the molar 
extension coefficient of chromophore (1.56 × 105 M-1 cm-1) [23]. 
Protein estimation 
The protein content was measured according to the method of 
Lowry et al. (1951), using bovine serum albumin as standard and 
expressed as µg protein / mg of tissue [24]. 
Histopathology 
Histopathological evaluation of the cerebral cortex of rat brains was 
performed. The brains were excised and immediately fixed in 10% 
buffered formalin. The cerebral cortex was sectioned from the brain, 
which was embedded in paraffin after being dehydrated in alcohol. 
Five-micrometer thick serial histological sections were obtained 
from the paraffin blocks by using microtome and stained with 
hematoxylin and eosin. The sections were examined under light 
microscope (Olympus, Japan) and photomicrographs were taken. 
Statistical analysis 
Data was subjected to one-way analysis of variance (ANOVA) 
followed by Dunnett’s test and results were expressed as mean ± 
SEM. 
RESULTS  
Effect of nebivolol on number of ambulations, rearings and 
latency to reach to the central area of open field test 
Significant (P<0.05) reduction in number of ambulations and 
rearings was observed in aluminium chloride treated group as 
compared to control group on days 15th, 25th and 35th. Also, latency 
to reach the central area in the open field was significantly (P<0.05) 
increased as compared to control group. Administration of nebivolol 
(10 mg/kg) showed significant (P<0.05) increase in both number of 
ambulations and rearings on 25th and 35th day.  
Nebivolol also significantly (P<0.05) reduced the latency to reach to 
the central area on 25th and 35th day as compared to aluminium 
chloride treated group. Selegiline (as standard drug) showed 
promising improvement in number of ambulations, rearings and 
latency to reach to the central area in open field test (Fig. 1). 
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Fig. 1: Effect of nebivolol on a) number of ambulations b) number of rearings c) latency to enter central area in open field test. 
All values are expressed as mean ± SEM. (n = 6). #Compared with control group, *Compared with chronic aluminium treated group; #,*P<0.05, nsNon-
significant (One way ANOVA followed by Dunnett’s test). 
 
Effect of nebivolol on transfer latency in modified elevated plus 
maze test (mEPM) 
In mEPM test, the animals treated with aluminium chloride 
exhibited significant (P<0.05) increase in transfer latency compared 
to control group. Treatment with nebivolol for 5 weeks significantly 
(P<0.05) reduced transfer latency on both days 34th and 35th as 
compared to aluminium treated group. Selegiline also significantly 
(P<0.05) decreased transfer latency as compared to aluminium 
chloride treated group (Fig. 2). 
 
 
Fig. 2: Effect of nebivolol on transfer latency on days 34th and 35th in mEPM test. 
All values are expressed as mean ± SEM. (n = 6). #Compared with control group, *Compared with aluminium treated group; #,*P<0.05, nsNon-
significant (One way ANOVA followed by Dunnett’s test). 
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Biochemical Estimations 
Effect of nebivolol on aluminium-induced alterations in rat 
brain SOD, CAT and GSH 
Chronic exposure to the aluminum significantly (P<0.001) decreased 
the levels of SOD, CAT and GSH as compared to control group, 
indicating oxidative stress. Pretreatment with nebivolol (10 mg/kg) 
significantly (P<0.001) increased the levels of SOD, CAT and GSH as 
compared aluminium treated group.  
Selegiline also showed significant increase in the levels of SOD, CAT 
and GSH (Table 1). 
Effect of nebivolol on aluminium-induced alterations in rat 
brain on LPO 
Exposure to the aluminum led to significant increase in LPO level. 
Pretreatment with nebivolol significantly (P<0.001) reduced 
elevated level of LPO. Selegiline also significantly decreased LPO 
level (P<0.001) (Table 1). 
 
Table 1: Effect of nebivolol on aluminium-induced alterations in rat brain CAT, GSH, SOD and LPO levels 
Treatments CAT 
(μ moles of H2O2 decomposed/mg 
protein/min) 
GSH 
(μ moles of GSH/mg 
protein) 
SOD 
(% inhibition of 
reduction of NBT) 
LPO 
(n moles of MDA/mg 
protein) 
Control 7.12 ± 0.8 7.67 ± 0.4 78.97 ± 0.2 7.48 ± 0.3 
Aluminium chloride (50 
mg/kg, p.o.) 
4.93 ± 0.1### 2.80 ± 0.1### 64.04 ± 3.1### 17.80 ± 0.6### 
Al + nebivolol 
(10 mg/kg, p.o.) 
 6.54 ± 0.3***  6.47 ± 0.3*** 74.83 ± 0.3*** 10.64 ± 0.3*** 
Al + selegiline 
(0.49 mg/kg, p.o.) 
 6.91 ± 0.1*** 
 
 7.17 ± 0.1*** 
 
78.47 ± 0.1*** 
 
11.38 ± 0.4*** 
 
All values are expressed as mean ± SEM. (n = 5). #Compared with control group, *Compared with aluminium treated group. ###,*** P<0.001.(One way 
ANOVA followed by Dunnett’s test).  
 
Histopathological changes 
The section of cerebral cortex (haematoxylin and eosin stained) 
from control group showed normal architecture. Aluminium treated 
group revealed presence of ghost cells, haemorrhage and vacuolated 
cytoplasm, suggesting neurotoxicity induced by aluminium.  
A section of the cerebral cortex of aluminium group pretreated with 
nebivolol and selegiline showed absence of ghost cells, vacuolated 
cytoplasm and hemorrhage with normal architecture demonstrating 
protection from aluminium-induced changes as compared to 









Fig. 3: Histopathological changes of cerebral cortex of rats in different groups. 
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A: Control group, histological structure of cerebral cortex showing 
normal architecture. 
B1 and B2: aluminium treated group revealed the presence of ghost 
cells (G), vacuolated cytoplasm (S), and haemorrhage (H).  
C and D: Nebivolol and selegiline treated groups showed absence of 
ghost cells, vacuolated cytoplasm and hemorrhage with normal 
architecture of cerebral cortex indicating protection from 
aluminium-induced changes in the cerebral cortex as compared to 
aluminium group. 
DISCUSSION 
The present study investigated the neuroprotective effects of 
nebivolol on aluminium-induced neuronal toxicity. Bowdler and co-
workers proved that aluminium exposure in animals and humans 
results in behavioral changes and intellectual impairment [25]. The 
results of the present study indicated that chronic exposure to 
aluminium showed significant reduction in motor activity in open 
field test. The aluminium chloride treated animals showed decrease 
in the number of ambulations, rearings with increase in latency to 
reach to the central area of open field. This indicated that aluminium 
has significantly affected the motor activity. Nebivolol showed 
significant improvement in all the behavioral parameters in open 
field. Pretreatment with nebivolol produced significant reduction in 
latency to reach to the central area and increased both number of 
ambulations and rearings, suggesting improvement in aluminium-
induced behavioral alterations.  
The mEPM test was used for testing the learning and memory. In 
mEPM test, aluminium chloride treated animals showed significant 
increase in transfer latency. This is an indication of impairment of 
memory. Administration of nebivolol (10 mg/kg) significantly 
reduced transfer latency on days 34th and 35th, indicating retention 
of memory. Selegiline also significantly decreased the transfer 
latency.  Long term exposure to aluminium causes oxidative stress 
and alterations in brain antioxidant enzymes. The aluminium-
induced neurotoxicity could be linked to the neurodegeneration 
caused by elevation in oxidative stress and deterioration of 
intracellular signal transduction pathways along with deposits of 
extracellular senile plaques and loss of synaptic contacts [26]. The 
results of the present study showed that chronic exposure to 
aluminium significantly decreased the levels of oxidative stress 
indices such as SOD, CAT and GSH with increase in LPO and protein 
oxidative products. Oxidative damage of the cerebral cortex in rats 
during aging and oxidative stress is responsible for impairment of 
cognitive functions [27]. Administration of nebivolol significantly 
elevated the levels of defensive antioxidant enzymes with 
concomitant decrease in LPO; thus indicating restoration of the 
oxidative stress indices in the rat brains. SOD plays an important 
role in detoxifying the superoxide radical to H2O2 by glutathione 
peroxidase at the expense of GSH. Therefore, GSH is an essential 
cofactor for antioxidants like catalase, glutathione peroxidase etc. 
Administration of nebivolol in aluminium-treated rats prevented the 
depletion of GSH level significantly, suggesting that it is effective in 
preventing the oxidative damage associated with aluminium 
exposure. Hence, we can propose that probably elevation of such 
enzymes could be one mechanism by which nebivolol counters 
aluminium-induced neurotoxicity. 
The cerebral cortex was selected for histopathology because 
aluminium affects the cortex region more severely than any other 
area of the central nervous system. This brain region is known to be 
particularly susceptible in Alzheimer’s disease and have an 
important role in learning and memory functions [28]. Exposure of 
aluminium, led to marked histopathological alterations in the 
cerebral cortex, including neuronal degeneration as cytoplasmic 
vacuolization, haemorrhage and ghost cells. Administration of 
nebivolol (10 mg/kg, p.o.) and selegiline (0.49 mg/kg, p.o.) to 
aluminium fed rats showed absence of histopathological changes in 
comparison to aluminium treated rats, showing their protective 
action. The results obtained after nebivolol treatment were identical 
with those of selegiline which confirms the neuroprotective effect of 
nebivolol. Selegiline, also known as l - deprenyl, is an irreversible 
MAO-B inhibitor, antidepressant, neuroprotectant and neuro rescue 
agent. Selegiline possesses the property to increase the survival of 
degenerating neurons, modulates dendritic branching pattern and 
facilitates the activity of dopaminergic neurons with at most 
selectivity [29]. Keeping these things in mind l-deprenyl was chosen 
as the standard drug.  The above discussion showed that aluminium 
neurotoxicity is mediated through oxidative damage and nebivolol 
has potential to counter this. Our data indicates that nebivolol could 
be beneficial in countering the aluminium-induced neurotoxicity at 
biochemical and behavioural levels. The antioxidant potential of 
nebivolol might play a key role in the observed therapeutic 
outcomes against aluminium-induced neurotoxicity. 
CONCLUSION 
We conclude that, nebivolol exhibits prominent antioxidant and 
neuroprotective activity against aluminium-induced neuronal 
degeneration and its use in the patients suffering from hypertension 
along with neurodegenerative disorders can be encouraged.  
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